S1PR2 and S1PR3 as Emerging Targets for Treatment of Chronic Pain
Abstract
Chronic pain has posed a serious challenge for many people’s daily life all over the world, with approximately 41% of Europeans in developing countries suffering it. Until recently, major treatments have relied on agents such as nonsteroidal anti-inflammatory drugs (NSAIDs) and narcotics, which, however, have become less acceptable due to side-effects. Therefore, novel classes of pain-relievers are urgently needed to fill this void and improve the life quality of patients.
Sphingosine-1-phosphate (S1P) is one of the most notable lysophospholipids, whose role on pain generation has been increasingly recognized. Drugs targeting sphingosine-1-phosphate receptors (S1PRs) could be developed as novel analgesics, either as monotherapy or potential adjuncts. In this review, recent advances of the roles of S1PRs in peripheral sensory aspects are summarized, especially S1PR3 and S1PR2.
References
[2] Mair N, Benetti C, Andratsch M, Leitner MG, Constantin CE, Camprubi-Robles M, et al. Genetic evidence for involvement of neuronally expressed S1P(1) receptor in nociceptor sensitization and inflammatory pain. PLoS One. 2011;6(2):e17268.
[3] Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol. 2011;11(6):403-15.
[4] Zhang YH, Fehrenbacher JC, Vasko MR, Nicol GD. Sphingosine-1-Phosphate Via Activation of a G-Protein-Coupled Receptor(s) Enhances the Excitability of Rat Sensory Neurons. Journal of Neurophysiology. 2006;96(3):1042-52.
[5] Camprubi-Robles M, Mair N, Andratsch M, Benetti C, Beroukas D, Rukwied R, et al. Sphingosine-1-Phosphate-Induced Nociceptor Excitation and Ongoing Pain Behavior in Mice and Humans Is Largely Mediated by S1P3 Receptor. Journal of Neuroscience. 2013;33(6):2582-92.
[6] Hill RZ, Hoffman BU, Morita T, Campos SM, Lumpkin EA, Brem RB, et al. The signaling lipid sphingosine 1-phosphate regulates mechanical pain. eLife. 2018;7.
[7] Xie W, Strong JA, Kays J, Nicol GD, Zhang J-M. Knockdown of the sphingosine-1-phosphate receptor S1PR1reduces pain behaviors induced by local inflammation of the rat sensory ganglion. Neuroscience Letters. 2012;515(1):61-5.
[8] Welch SP, Sim-Selley LJ, Selley DE. Sphingosine-1-phosphate receptors as emerging targets for treatment of pain. Biochemical Pharmacology. 2012;84(12):1551-62.
[9] Sim-Selley LJ, Goforth PB, Mba MU, Macdonald TL, Lynch KR, Milstien S, et al. Sphingosine-1-phosphate receptors mediate neuromodulatory functions in the CNS. Journal of Neurochemistry. 2009;110(4):1191-202.
[10] Chi XX, Nicol GD. The Sphingosine 1-Phosphate Receptor, S1PR1, Plays a Prominent But Not Exclusive Role in Enhancing the Excitability of Sensory Neurons. Journal of Neurophysiology. 2010;104(5):2741-8.
[11] Meng H, Lee VM. Differential expression of sphingosine-1-phosphate receptors 1-5 in the developing nervous system. Developmental Dynamics. 2009;238(2):487-500.
[12] Satsu H, Schaeffer M-T, Guerrero M, Saldana A, Eberhart C, Hodder P, et al. A sphingosine 1-phosphate receptor 2 selective allosteric agonist. Bioorganic & Medicinal Chemistry. 2013;21(1 7 ):5373-82.
[13] Li C, Li J-n, Kays J, Guerrero M, Nicol GD. Sphingosine 1-phosphate enhances the excitability of rat sensory neurons through activation of sphingosine 1-phosphate receptors 1 and / or 3. Journal of Neuroinflammation. 2015;12(1).
[14] Gu Q, Hou J-C. S1PR2 deficiency enhances neuropathic pain induced by partial sciatic nerve ligation. Turkish Journal of Medical Sciences. 2019;49(1):412-21.
[15] Li Y, Li H, Han J. Sphingosine-1-phosphate receptor 2 modulates pain sensitivity by suppressing the ROS-RUNX3 pathway in a rat model of neuropathy. Journal of Cellular Physiology. 2020;235(4):3864-73.
[16] Li C, Chi XX, Xie W, Strong JA, Zhang JM, Nicol GD. Sphingosine 1-phosphate receptor 2 antagonist JTE-013 increases the excitability of sensory neurons independently of the receptor. Journal of Neurophysiology. 2012;108(5):1473-83.
[17] Li M-H, Swenson R, Harel M, Jana S, Stolarzewicz E, Hla T, et al. Antitumor Activity of a Novel Sphingosine-1-Phosphate 2 Antagonist, AB1, in Neuroblastoma. Journal of Pharmacology and Experimental Therapeutics. 2015;354(3):261.
[18] Stepanovska B, Huwiler A. Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases. Pharmacological Research. 2020;154.
[19] Doyle T, Finley A, Chen Z, Salvemini D. Role for peroxynitrite in sphingosine-1-phosphate-induced hyperalgesia in rats. Pain. 2011;152(3):643-8.
[20] Devor M. Ectopic discharge in Aβ afferents as a source of neuropathic pain. Experimental Brain Research. 2009;196(1):115-28.
Copyright (c) 2021 Mingxin Xie
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
